Fig. 1

NR1B2 were down-regulated in TCGA database and predicts poor clinical outcome. a. NR1B2 expression in KIRC and other cancer types in TCGA dataset (KIRP: Kidney renal papillary cell carcinoma; BLCA: bladder cancer; BRCA: breast cancer; HNSC: Head and Neck squamous cell carcinoma; LUAD: Lung adenocarcinoma; THCA: Thyroid carcinoma; UCEC: Uterine Corpus Endometrial Carcinoma). b-c. Overall survival (b) and disease-free survival (c) curve of KIRC patients with low (n = 258) and high (n = 257) NR1B2 expression. d-i. Relative expression levels of NR1B2 in TCGA database with pathological stage (d), tumor stage(e), lymph node invasion(f), metastasis status (g), recurrence status(h), hemoglobin level(i). j. The diagnostic value of NR1B2 in TCGA database was evaluated using a receiving operating character (ROC) curve. k-l. Univariate (k) and multivariate(l) analysis of the hazard ratios (HRs) showed that the down-regulation of NR1B2 may be an independent prognostic factor for the overall survival rates in TCGA database. The HRs are presented as the means (95% confidence interval). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001